Erectile Dysfunction Market Size, Share & Industry Analysis, By Treatment Type (Drugs [Sildenafil, Tadalafil, Vardenafil, Avanafil, Others] Penile Implants, Penis Pumps, Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Pharmacies, Others)and Regional Forecast, 2024-2032

Erectil dysfunction (ED) is the inability to get or keep an ecrection firm enough to have sexual intercourse. Ocassional ED isn’t uncommon which men experience during the times of stress. However, frequent erectile dysfunction is a sign of health problem and need to be treated. Common casuses of erectile dysfunction are cardiovascular disease, diabetes, hypertension, high cholesterol, stress, etc,. Rising number of cases of erectile dysfunction, sedentary lifestyle and increasing habit of alcoholism and smoking, technological advancemnts in the treatment devices, and frequent product launches and product approvals are some of the factors that are acting as the catalysts for erectile dysfunction treatment market during the forecast period. For instance, in March 2019, VIVUS Inc. announced that the Ministry of Health of the Russian Federation approved the 50 mg, 100 mg, and 200 mg avanafil tablets for tehtreatment of erectile dysfunction.

The erectile dysfunction market is expected to register a significant growth during the forecast period due to factors such rising number of cases of erectile dysfunction, sedentary lifestyle, increasing habit of alcoholism and smoking, and growing number of awareness programs conducted by government. However, high cost of penile implants is one of the major factors anticipated to restrict the growth of erectile dysfunction market.

Market Segmentation:

Globally, the erectile dysfunction market can be segmented on the basis of the treatment type, route of administration, end user, and region. Based on the treatment type, the market can be segmented into drugs, penile implants, penis pumps, and others. Based on drugs, the market can be further segmented into sildenafil, tadalafil, vardenafil, avanafil, and others. Based on end user, the market can be segmented into hospitals & clinics, ambulatory surgery centers, pharmacies, and others. Geographically, the erectile dysfunction market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the erectile dysfunction market are Pfizer Inc., Bayer AG, Eli Lilly and Company., Apricus Biosciences, Inc., Mylan N.V., Lupin, GlaxoSmithKline plc., Boston Scientific Corporation, Dr. Reddy’s Laboratories, Sanofi, and other prominent players.

Key Insights:

• Key Industry Trends


• Prevalence of Erectile Dysfunction


• New Product Launches


• Key Industry Developments Mergers, Acquisitions, And Collaborations

Regional Analysis:

Geographically, the erectile dysfunction market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is projected to account for maximum share of the erectile dysfunction market. The dominance is attributable to the increasing incidence of erectile dysfunction, well developed healthcare sector, and easy availability of treatment devices. For instance, according to article published by The Cleveland Clinic Foundation, in 2018, 617,715 new cases of erectile dysfunction were reported in United States. Europe is anticipated to hold second largest market share in global market. Increasing geriatric population and various product launches by the key market players is likely to spur the market growth in this region. On the other hand, Asia Pacific is expected to register the highest CAGR. Rising demand for drugs such as sildenafil, tadalafil due to growing patient pool of erectile dysfunction is likely to propel the market growth of this region.

The market in Latin America and the Middle East & Africa are in nascent stage. However, growing patient awareness regarding the disease and the drug in these regions are likely to help witness a considerable growth in the market in the upcoming years.

Erectile Dysfunction Market Industry Developments

• In February 2019, Dr. Reddy’s Laboratories launched Tadalafil tablets for the treatment of erectile dysfunction in the U.S. market.


• In September 2019, Lupin launched Sildenafil tablets for the erectile dysfunction treatment in the U.S. market.


• In July 2019, Boston Scientific Corporation launched a natural-feeling implant to treat erectile dysfunction.